Publications of Olivier BONHOMME
Bookmark and Share    
Full Text
See detailAsthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection
CALMES, Doriane ULiege; Graff, Sophie ULiege; MAES, Nathalie ULiege et al

in Journal of Allergy and Clinical Immunology: In Practice (2020)

Detailed reference viewed: 32 (1 ULiège)
Full Text
See detailFirst report of probe based confocal laser endomicroscopy during medical thoracoscopy.
BONHOMME, Olivier ULiege; DUYSINX, Bernard ULiege; HEINEN, Vincent ULiege et al

in Respiratory Medicine (2019), 147

Probe based confocal laser endomicroscopy (pCLE) is a new optical endoscopic technique, generating fluorescent light emission from the tissue of interest and allowing in vivo live imaging at a cellular ... [more ▼]

Probe based confocal laser endomicroscopy (pCLE) is a new optical endoscopic technique, generating fluorescent light emission from the tissue of interest and allowing in vivo live imaging at a cellular level ("optical biopsies"). To the best of our knowledge, this article is the first to present pCLE images during medical thoracoscopy. We present here 3 different patients referred for various health problems. A precise description of pleural cavity pCLE images after intravenous fluorescein injection (a fluorophore) together with corresponding macroscopical and histological studies is performed. This led to the diagnosis of normal pleura in one case, carcinomatous pleuritis in another case and a malignant mesothelioma in the third case. We believe that optical biopsies could help clinicians to make an early diagnosis, thereby allowing rapid therapeutic intervention (talc pleurodesis for example). Furthermore, it could help to guide biopsies when affected zones are not obvious to macroscopic examination. In a near future, new fluorophores could be developed to stain some pathophysiological processes, therapeutic targets, or enzymes activities bringing new insights in endoscopic pleural disease work-up. [less ▲]

Detailed reference viewed: 63 (6 ULiège)
Full Text
See detailBiomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.
BONHOMME, Olivier ULiege; ANDRE, Béatrice ULiege; GESTER, Fanny ULiege et al

in Rheumatology (Oxford, England) (2019)

SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc ... [more ▼]

SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease. [less ▲]

Detailed reference viewed: 54 (11 ULiège)
Full Text
See detailLe medicament du mois Trimbow(R) ou triple association bronchodilatatrice et anti-inflammatoire en aérosol dans la broncho-pneumopathie chronique obstructive
Corhay, Jean-Louis ULiege; BONHOMME, Olivier ULiege; GUIOT, Julien ULiege

in Revue Médicale de Liège (2018), 73(9), 480-484

Single-inhaler triple therapy in extrafine solution combining an inhaled corticosteroid (ICS), the dipropionate of beclometasone, a long acting ss2-agonist (LABA), the fumarate of formoterol and an long ... [more ▼]

Single-inhaler triple therapy in extrafine solution combining an inhaled corticosteroid (ICS), the dipropionate of beclometasone, a long acting ss2-agonist (LABA), the fumarate of formoterol and an long-acting muscarinic antagonist (LAMA), the bromide of glycopyrronium, was developed for the treatment of the chronic obstructive pulmonary disease (COPD). Trimbow(R) is the first triple therapy in spray with fixed dose and containing 3 pharmacological agents (LABA-LAMA-ICS). Clinical trials show that Trimbow(R) improves numerous parameters such as the respiratory function, the quality of life, the symptoms and the rate of moderate to severe exacerbations while being tolerated well. These results justify its use in severe and very severe COPD with exacerbations in spite of treatment by LABA-LAMA or LABA-ICS. In this article, we present a brief synthesis of the main recent clinical trials on Trimbow(R), its comparison with other pharmacological agents/associations regularly used in the treatment of COPD, as well as some practical information on its use in routine. [less ▲]

Detailed reference viewed: 79 (1 ULiège)
Full Text
See detailComment je traite ⋯ une fibrose pulmonaire idiopathique
GUIOT, Julien ULiege; Duysinx, Bernard ULiege; BONHOMME, Olivier ULiege et al

in Revue Médicale de Liège (2017), 72(9), 381-383

Idiopathic pulmonary fibrosis (IPF) is a rare disorder of unknown origin, which is associated with a high mortality and whose incidence has been increasing for several years. Nowadays there are two anti ... [more ▼]

Idiopathic pulmonary fibrosis (IPF) is a rare disorder of unknown origin, which is associated with a high mortality and whose incidence has been increasing for several years. Nowadays there are two anti-fibrotic therapies (pirfenidone - nintedanib) known to reduce significantly the decline in respiratory function tests of patients suffering from this condition. The only curative therapeutic option remains the pulmonary transplantation whose accessibility remains limited. Pulmonary rehabilitation is also central in the treatment of patients. A major challenge for patients remains early and aggressive management to reduce as early as possible the evolution towards severe pulmonary fibrosis. [less ▲]

Detailed reference viewed: 130 (15 ULiège)
Full Text
See detailRéduction des exacerbations dans la bronchopneumopathie chronique obstructive: défi en 2017
Debrus, C.; BONHOMME, Olivier ULiege; Corhay, Jean-Louis ULiege

in Revue Médicale de Liège (2017), 72(2), 74-80

Chronic Obstructive Pulmonary Disease (COPD) is the 4th leading cause of death in our country. Exacerbations play a major role in the course of the disease. Their consequences are multiple: accelerated ... [more ▼]

Chronic Obstructive Pulmonary Disease (COPD) is the 4th leading cause of death in our country. Exacerbations play a major role in the course of the disease. Their consequences are multiple: accelerated decline in lung function, deterioration in patients' quality of life and well-being, decreased physical activity, increased morbidity and mortality related to COPD, significant economic implications on health budgets and workplace absenteeism. Reducing the number of exacerbations in patients with COPD therefore represents a major challenge in the treatment of this disease. In this article, we underline the importance of these exacerbations and review the therapeutic means available in 2017 to prevent them. [less ▲]

Detailed reference viewed: 47 (3 ULiège)